HEALTH TECHNOLOGY

KORE and Myia Health Join Forces to Enable Remote Home-Based Care of Chronically Sick Patients

KORE | September 21, 2021

KORE and Myia Health Join Forces to Enable Remote Home-Based Care of Chronically Sick Patients

KORE, a global leader in Internet of Things (IoT) services and solutions, today announced that it has teamed up with Myia Health, an enterprise platform for healthcare delivery in the home, to provide major hospitals with software and IoT managed services that ensure IoT devices are kitted and shipped to patients who are being treated where they live.

 

The COVID-19 pandemic accelerated the pace of digital transformations in all industries, especially in the healthcare sector. "The connected health segment has experienced 18 years' worth of innovation and IoT adoption during the 18 months of the pandemic. And the pace isn't slowing down. Virtual patient care and remote patient monitoring have become the go-forward norm in part because IoT has matured, and we can service this demand with our one-stop-shop IoT enablement services.

KORE President and CEO Romil Bahl

 

Powered by advanced data analytics, Myia's platform connects clinical actions with patient outcomes and identifies patients with the greatest need for high-touch care. When a patient is identified as vulnerable in a population or upon discharge from the hospital, KORE and Myia collaborate to handle the device logistics and deploy Myia's patient and clinician software technology that allows healthcare providers to manage patients' health in a continuous and preventative manner from the home.

 

Hospitals have consistently encountered the same significant logistics hurdles, though, as they attempt to build their virtual care/virtual hospital strategies. The virtual care experience is possible because of the advancement in market-ready health monitoring devices and improved choice in and reliability of the required connectivity for those devices. Take, for example, a hospital located in the mid-western part of the U.S. It typically adds 5,000 remote patients annually, and each of those patients has on average three health monitoring devices.

 

Before leveraging KORE, this hospital was handling the sourcing and logistics for 15,000 devices that were out in the field. The hospital quickly realized that it made more sense to outsource these services to a third party to manage the sourcing, servicing, kitting and retrieval of those devices. "Hospitals prefer to stick to their knitting and focus on giving care, not the details of ensuring a heart monitor device has arrived at the home of the patient and will work out of the box, including connectivity and secure flow of data," Bahl said.

 

Myia utilizes its advanced analytics and machine learning to partner with major hospital systems to provide the digital infrastructure of their virtual operations, which fuels and optimizes patient outcomes, clinical operations and the economics of these state-of-the-art virtual command centers where many thousands of patients can be monitored and preventatively managed in near-real time. KORE plays a fundamental role in the success of these endeavors because it handles all of the managed services and logistics of making sure the right devices are delivered to the right patients at the right time.

Myia CEO and Co-Founder, Simon MacGibbon

 

With a chronic heart failure patient, for example, KORE kitting and logistics capabilities are critical to ensure the cellular connected sensors and tablet arrive at the home of the patient with the proper software and configuration. KORE integrates sensors that capture vital health stats such as blood pressure and oxygen levels along with temperature and patient weight. KORE testing ensures a flawless out-of-the-box experience at a most critical point in the patient's recovery process.

 

"The ultimate outcome is that we're helping keep people healthy after an acute event so that they don't have to go back to the hospital and are as well-managed and healthy as possible. This ultimately will help improve patient outcomes, and drive down overall healthcare costs and utilization," MacGibbon said. 

 

As hospitals move into the new norm of virtual care, they are no longer just hospital caregivers. The hospitals now have a highly complex, home-based logistics piece of their business that they have never before encountered. AI, technology, and specialized managed services are enabling hospitals to make their visions for virtual care a reality, as effectively as possible, while ensuring the behind-the-scenes processes are as streamlined and cost-efficient as possible.

 

About KORE
KORE is a pioneer, leader, and trusted advisor delivering mission critical IoT solutions and services. We empower organizations of all sizes to improve operational and business results by simplifying the complexity of IoT. Our deep IoT knowledge and experience, global reach, purpose-built solutions, and deployment agility accelerate and materially impact our customers' business outcomes.

 

About Myia Health
Myia is the one platform that seamlessly moves across the care continuum and optimizes patient outcomes, clinical operations, and the economics of delivering care beyond the hospital and in the home.  Our future-proof enterprise platform is transforming the nation's most innovative healthcare organizations as they transition to value.

Spotlight

Do you take the local option or the best option when it comes to healthcare? Here are 10 good reasons to potentially travel for medical care from your partners at ARCHIMEDICX - Connecting Patients to the World's Best Hospitals.


Other News
HEALTH TECHNOLOGY

The GIANT Health Event 2021. Early bird tickets on sale now

GIANT Health | October 13, 2021

Europe's greatest festival of Health Tech Innovation | 30th Nov - 1st Dec 2021 Join us at GIANT this year and immerse yourself in Europe's greatest festival of healthcare innovation. Find inspiration from global leading innovators, and discover the advances in technology that are revolutionizing healthcare provision. GIANT 2021 is set to be our biggest event yet so don't miss out. GIANT Health event is an invaluable, cost-effective global hybrid event. Combining both a real-world physical trade show and multiple conferences in central London, as well as a sophisticated and engaging virtual event based on GIANT Health’s proprietary Virtual Event Platform. Learn more about Digital Therapeutics. Would you like to network with 1000s and 1000s of Europe's leading healthcare and technology innovators, hospital leaders, health-sector investors, and entrepreneurs? Over 400 speakers will convene in 15+ conference at the massive GIANT Health Event, 30 November - 1 December, 2021. Come join us in person or remotely. Early Bird tickets are now available. CLAIM YOUR TICKET HERE A special promotional code which allows to save up to 25% on top is available for our subscribers: MEDIA25 See you there! Media contact: GIANT Health Events Ltd Olga Nosova +44 20 8144 9779 Olga@GIANT.health

Read More

HEALTH TECHNOLOGY

PulsePoint Releases Next Generation Health Media Platform With Advanced Automation And AI

PulsePoint | July 06, 2021

PulsePoint, a technology company revolutionizing health decision-making in real-time, today announced the next generation launch of its digital media buying platform, Life by PulsePoint™. Its enhanced AI and automation simplifies and supercharges the media planning, activation, and optimization processes. Designed for the self-serve programmatic trader, these updates promote efficiencies and surface predictive and in-flight campaign analytics for quick strategic decisioning to yield higher media return on investment. Built upon PulsePoint's extensive data foundation, Genome™, that proactively uses microdata to capture attention when intent is signaled, Life is the leading healthcare end-to-end programmatic platform. Life's automated machine learning and AI allows marketers to quickly create highly-customized segments that classify populations in real-time, and deliver sequential messaging to drive customer actions in the moment and across the health journey. This next generation of the Life platform includes: • Advanced media planning innovations: Life offers an AI-powered forecasting tool used to run simulations to generate predictive performance metrics and intelligent audience insights. This makes it easier for marketers to preview budgets and ideate and adjust tactics to obtain their desired campaign outcomes, all before a single dollar is spent. Each forecast is powered by detailed supply and channel insights, like expected delivery, and campaign performance can be viewed by a variety of dimensions, including creative types, domains/apps, condition categories, healthcare professional specialties, geographies, among others. • Better campaign management with advanced dashboard: An automated and real-time view of line item performance and pacing gives traders a deeper, more granular look into their campaigns, making it easier for them to optimize their spend based on flight delivery and anticipate new incremental opportunities. The dashboard not only surfaces key numbers, but it also includes dynamic performance charts to uncover real-time campaign insights. • Turnkey PMP (private marketplaces) deal builder: Enhanced with turnkey end-to-end functionality, self-serve traders can now enable the deals that they negotiated directly with publishers and/or SSPs through Life's UI, decreasing the time it takes to launch PMPs. "Life was built for the healthcare marketer to simplify and optimize marketing campaigns," said Andrew Stark, CRO of PulsePoint. "Our newest capabilities increase efficiencies through advanced forecasting and real-time performance optimization, enabling more control and enhanced campaign management." Life by PulsePoint provides access to over 110 billion daily impressions across more than 2 million health pages, reaching 1.8M+ opted-in, verified healthcare professionals and over 90% of the online U.S. population. This release is just another step in PulsePoint's journey to deliver personalized messaging at each stage of the health journey using predictive insights built on real-time data. The company was recently acquired by Internet Brands, a KKR portfolio company and owner of WebMD Health Corp. PulsePoint's teams will continue to operate as their own division from their existing hubs in New York, San Francisco, and London. About PulsePoint PulsePoint is a leading technology company that uses real-world data in real-time to optimize campaign performance and revolutionize health decision-making. Leveraging proprietary datasets and methodology, PulsePoint targets healthcare professionals and patients with an unprecedented level of accuracy—delivering unparalleled results to the clients we serve.

Read More

HEALTH TECHNOLOGY

Future Health announced today that it has completely digitalised its annual in-person event at ExCeL London

Future Health | March 02, 2021

Future Health has completely rebranded during lockdown, and the flagship face-to-face event Future Health Innovations at ExCeL is now complemented by a global virtual conference series, under the brand UK Health Week. Free for delegates to attend, it is CPD and CME accredited. Participants will be able to connect, meet buyers and partake in cross border purchasing, education and deal making, enabling an increased ROI and profitable encounters with its AI powered networking software. Further Health Weeks are being rolled out around the world over the course of the coming months, and will be territory specific. Dawn Barclay-Ross, Event Director commented: “I think there will always be a place for face-to-face events; and we are contracted with ExCeL for a live ‘in person’ event four years in advance to 2025. However, as a result of international travel restrictions, health professionals in global markets are looking for on-line engagement”. Future Health offers buyers and sellers the ability to operate on line, and to research and access the products and services that their hospitals and citizens desperately need. Dawn concluded, “In the immediate post COVID era, health buyers want to be able to operate from the comfort of their desk or smart device, and they now can, from literally anywhere in the world”. AboutFuture Health Future Health is an independent exhibition and conference organiser, based in London in the UK. For further information regarding exhibiting, visiting and sponsorship opportunities at Future Health Innovations or UK Health Week Please call +44 (0) 208 012 8511 Email: hello@futurehealthinnovations.com or to sign up to the Future Health platform, register at www.futurehealthinnovations.com

Read More

HEALTH TECHNOLOGY

L2Mtech GmbH Receives CE Mark Approval on 6(SIX) products for Cardiovascular and Endovascular Applications

L2Mtech | February 17, 2021

CE Mark Approval for LimusTrack™, Sirolimus Eluting Coronary Stent System for Cardiovascular Applications. CE Mark Approval for LomiFlow™, Paclitaxel Drug Eluting Balloon for Cardiovascular Applications CE Mark Approval for PearlFlow™, Paclitaxel Drug Elutin Balloon for Endovascular Applications CE Mark Approval for PearlFlow NS™, Self Expandable Nitinol Stent System for Endovascular Applications CE Mark Approval for FlexiTrack 018™, Peripheral Balloon Catheter for Endovascular Applications CE Mark Approval for FlexiTrack 035™, Peripheral Balloon Catheter for Endovascular Applications Bonn, Germany – L2Mtech GmbH has announced the award of its first CE Mark approval on Six (6) products: LimusTrack™ : Sirolimus Coated Cobalt Chromium Stent with biodegradable polymer for the treatment of coronary artery disease, de novo lesions, restenosis lesions. LomiFlow™ : Paclitaxel Coated balloon catheter for the treatment of coronary artery disease, small vessels, dilatation of de novo lesions, in-stent restenosis (ISR) cases. PearlFlow™ : Paclitaxel Coated balloon catheter for the treatment of peripheral arterial disease, PTA, dilatation of stenotic segments or lesions in peripheral arteries. PearlFlow NS™ : Self-Expanding Nitinol Stent System for the treatment of peripheral arterial disease, de novo lesions, lesions in femoropopliteal arteries. FlexiTrack 018™ : Peripheral Balloon Dilatation catheter for the treatment of peripheral arterial disease, dilatation of lesions in femoral, popliteal, tibial arteries. FlexiTrack 035™ : Peripheral Balloon Dilatation catheter for the treatment of peripheral arterial disease, dilatation of lesions in the SFA, femoral arteries. L2Mtech GmbH Founder and CEO Lalit Mamtani said ‘‘We are very excited to have been awarded our first CE Mark on six products, CE Mark approval represents a key milestone for L2Mtech GmbH and is a testament to the efficacy and safety of our innovative technology products for Cardiovascular and Endovascular applications.“ We now prepare to commercially launch the products in all markets where the CE Mark is recognized. With introduction of our innovative technology products in markets, we will be able to expand treatment options for the benefit of many millions of patients with coronary and peripheral artery disease around the world. About L2Mtech Founded in 2017, L2Mtech GmbH is a privately-owned multinational medical device company headquartered at Bonn, Germany. L2Mtech specializes in design, development, manufacture and commercialization of medical devices that are used by healthcare establishments globally. L2MTech will provide interventional physicians with innovative vascular devices including Drug Eluting Balloon manufactured in Europe.Our Core mission is to build a product portfolio focused on minimally invasive treatment for patients with cardiovascular,endovascular and vascular artery disease. For further information, please visit : L2MTech.de Media Contact: L2Mtech GmbH admin@L2Mtech.de +49 228 94730761

Read More

Spotlight

Do you take the local option or the best option when it comes to healthcare? Here are 10 good reasons to potentially travel for medical care from your partners at ARCHIMEDICX - Connecting Patients to the World's Best Hospitals.

Resources

Events